LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial

PURPOSE: In patients with advanced lung adenocarcinoma, the impact of LKB1 mutations on cytotoxic chemotherapy efficacy remains poorly explored. Here, we aimed at investigating the potential impact of LKB1 mutational status on chemotherapy efficacy in advanced non-small-cell lung cancer (NSCLC) pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Vernieri, Claudio, Ganzinelli, Monica, Rulli, Eliana, Farina, Gabriella, Bettini, Anna Cecilia, Bareggi, Claudia, Rosso, Lorenzo, Signorelli, Diego, Galli, Giulia, Lo Russo, Giuseppe, Proto, Claudia, Moro, Massimo, Indraccolo, Stefano, Busico, Adele, Sozzi, Gabriella, Torri, Valter, Marabese, Mirko, Massimo, Broggini, Garassino, Marina C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259832/
https://www.ncbi.nlm.nih.gov/pubmed/32467099
http://dx.doi.org/10.1136/esmoopen-2020-000748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259832/
https://www.ncbi.nlm.nih.gov/pubmed/32467099
http://dx.doi.org/10.1136/esmoopen-2020-000748

Ejemplares similares